Compare Amgen, Inc. (AMGN) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Delta Air Lines, Inc. — how do they compare? Amgen, Inc. trades at $356.38 (market cap $196.12B), while Delta Air Lines, Inc. trades at $85.96 (market cap $57.41B). The key difference: Amgen, Inc. is far larger — about 3.4× Delta Air Lines, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DAL | |
|---|---|---|
Market Cap | $196.12B | $57.41B |
Sector | Health | Industrials |
52-Week High | $388.16 | $93.66 |
52-Week Low | $271.18 | $51.15 |
Enterprise Value | $241.41B | $72.73B |
Dividend Yield | 2.77% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Delta Air Lines (DAL) trades at $87.39, down 1.81% today, but maintains a bullish technical outlook with strong support at $86. The company reported Q2 2026 EPS of $2.45, beating estimates by 64%, driven by premium demand and World Cup traffic benefits. Revenue growth remains robust at 14% year-over-year, with a net income margin of 6.87%. Analysts are overwhelmingly bullish with an 82% buy rating and a $106.07 price target, implying 21% upside. Cash flow trends show consistent operational strength, with 2025 net cash flow at $1.08 billion.
DAL presents a compelling investment case with earnings momentum, reasonable valuation (P/E 14.49), and analyst confidence. Key risks include fuel cost volatility and competitive pricing pressure, but strong corporate travel demand and dividend growth support long-term value. The stock's current dip offers a potential entry point near technical support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
